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Abstract: This study evaluates the contribution of peripheral biomarkers to comorbidities and clinical
findings in autism. Seventeen autistic children and age-matched typically developing (AMTD),
between three to nine years old were evaluated. The diagnostic followed the Diagnostic and Statistical
Manual of Mental Disorders 4th Edition (DMS-IV) and the Childhood Autism Rating Scale (CARS)
was applied to classify the severity. Cytokine profile was evaluated in plasma using a sandwich
type ELISA. Paraclinical events included electroencephalography (EEG) record. Statistical analysis
was done to explore significant differences in cytokine profile between autism and AMTD groups
and respect clinical and paraclinical parameters. Significant differences were found to IL-1β, IL-6,
IL-17, IL-12p40, and IL-12p70 cytokines in individuals with autism compared with AMTD (p < 0.05).
All autistic patients showed interictalepileptiform activity at EEG, however, only 37.5% suffered
epilepsy. There was not a regional focalization of the abnormalities that were detectable with EEG in
autistic patients with history of epilepsy. A higher IL-6 level was observed in patients without history
of epilepsy with interictalepileptiform activity in the frontal brain region, p < 0.05. In conclusion,
peripheral inflammatory markers might be useful as potential biomarkers to predict comorbidities in
autism as well as reinforce and aid informed decision-making related to EEG findings in children
with Autism spectrum disorders (ASD).
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1. Introduction
Autism spectrum disorders (ASD) are neurodevelopmental disorders defined by significantly
abnormal social interaction, impaired communication and language difficulties, and narrow patterns
of interests. Symptoms appear during infancy or childhood and generally are followed by a steady
course without remission. Symptoms gradually begin after the age of six months to become established
by age two or three years old and continue through adulthood, although generally more attenuated.
Growing data suggest the impact of immune dysfunction on neuron development and autism
outcome [1–8]. Changes in cytokine levels have been reported in cerebrospinal fluid (CSF) of patients
with autism, showing brain inflammation [6,7]. Previous reports on autism include findings regarding
changes in IL-1β, IL-10, IL-6, IL-17, and IL-12 cytokines and differential cellular immune response
associated with disease severity and impairment in behaviors in ASD [8–10]. In some cases, evidence
has also been provided regarding cytokine’s role in mediating suppression of both FoxP3 (+) and
FoxP3 (−) T regulatory cells in this disorder [11].
Evidence from other studies show an increased prevalence of epilepsy and/or abnormalities
in electroencephalography(EEG) in these children, as well as an increased risk of seizures at
puberty [12–16]. It is estimated that approximately one-third of children and adolescents with autism
experiences seizures [17,18], nevertheless the role of inflammation in autism and its contribution to
associated comorbidities, like epilepsy, continues to be a still unresolved question.
Evidence from several previous studies had marked the role of pro-inflammatory cytokines,
such as IL-1, IL-6, and TNFα, as main factors in the generation of abnormal behavioral and
electroencephalography patterns occurring in autism.The current study was designed to explore
changes in cytokine profile in autism and their relevance to clinical and paraclinical parameters.
This study evaluated the contribution of inflammation to clinical outcome and comorbidities in autism,
showing that peripheral inflammatory markers might be used to predict comorbidities in autism as
well as became useful to reinforce and aid informed decision-making related to EEG findings in these
affected children.
2. Materials and Methods
2.1. Study Subjects
The study considered seventeen children with clinical diagnosis of ASD and fifteen age-matched
typically developing (AMTD) children. The diagnosis was followed according to DSM-IV-TR 2000: the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Revision [19–22]. The autistic patient
group was between three and nine years old, including 12 male and 5 female patients. The patients
were also classified according disease severity. The Childhood Autism Rating Scale (CARS) test was
used by research reliable severity score [23,24]: 1 patient who has a CARS score of 37 or more was
classified as severe; 11 patients were classified with moderate severity having a CARS score between
32 and 37, and 5 patients were classified as mild, on account of their CARS score being below 32.
Informed consent was obtained from parents or caregivers of children to be included in the study.
The parents were also informed about the objective and benefits of the study as well as their right to be
excluded at any time, under their decision. The study was carried out in accordance with the Helsinki
norms and rights for human research and was approved by the Ethical Committee of the International
Center for Neurological Restoration. The clinical characteristics of all participants are summarized in
Table 1.
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Table 1. Clinical and demographic characteristics of autistic patients. CARS, Childhood Autism Rating
Scale; M, male; F, female.
Patient Age (Years) Sex CARS Score Severity
1 9 M 26 Mild
2 7.8 M 35.5 Moderate
3 7.8 M 36.5 Moderate
4 5 M 33 Moderate
5 6.1 M 36 Moderate
6 4 F 46 Severe
7 6.6 F 33.5 Moderate
8 4 M 36 Moderate
9 9.1 M 28 Mild
10 8 M 37 Moderate
11 5.2 F 36.5 Moderate
12 3 M 35.5 Moderate
13 3 F 27 Mild
14 7.2 M 34.5 Moderate
15 9.1 M 35 Moderate
16 5 F 30 Mild
17 5 M 31 Mild
2.2. EEG Assessments
Routine awake and sleep 60-minute-EEG or both were performed with a Medicid-5 digital
EEG system (Neuronic SA, Cuba), with 32 channels. Monopolar leads were employed, using Fpz
electrodes as reference. Moreover, electrodes placed over the superior and inferior rim were used in
order to record eye movement artifacts for easing their detection in the EEG records. EEG technical
parameters were: gain 20,000, pass-band filters 0.1–70 Hz, “notch” filter at 60 Hz, noise level of 2 lV(root
mean square), sampling frequency 200 Hz, and electrode–skin impedance never higher than 5 KX.
EEG analyses were performed by two board-certified electroencephalographers.
Type and localization of EEG epileptiform abnormalities in awake/sleep-EEG recordings were
evaluated. EEG studies were classified as epileptiform if spikes, sharp waves, or spike/slow waves
complexes were recorded. Abnormalities such as slowing of the background or other non-epileptic
pattern were not considered. All activity regarded as artefactual was excluded.
2.3. Cytokine Profile Measurement
2.3.1. Samples Collection
Peripheral blood samples were collected from each subject for serum analysis. Whole blood was
collected into ethylenediaminetetraacetic acid (EDTA) coated collection tubes. The tube was inverted
10 times to mix the blood with the EDTA, and stored on ice until further processing. In all cases, the
duration from collection to freezing was noted. Blood was separated by centrifugation at 1000× g in a
swinging bucket centrifuge pre-chilled to 4 ◦C. The plasma was harvested, placed into 200 µL aliquots,
and stored at −80 ◦C until cytokine analysis (no freeze-thaw cycles occurred before analysis).
2.3.2. Cytokine Analysis
Cytokine analysis was conducted using an array-based multiplex sandwich ELISA System
(Quantibody® Human Inflammation Arrays; QAH-INF-3, RayBiotech, Inc., Norcross, GA, USA) for the
simultaneous quantification of multiple cytokines/chemokines: Interleukin (IL)1α, IL1β, IL1 receptor
antagonist(IL-1ra), IL-2, IL-4, IL-5, IL-6 and its soluble receptor (IL-6sR), IL-7, IL-8, IL-10, IL-12p40,
IL-12p70, IL-13, IL-15, IL-16, IL-17, eotaxin, eotaxin-2, granulocyte colony-stimulating factor (G-CSF),
macrophage colony-stimulating factor (GM-CSF), Interferon (IFN)γ, monocyte chemotactic protein
(MCP)-1, macrophage inflammatory protein (MIP)-1α, MIP-1β, MIP-1γ, platelet-derived growth factor
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(PDGF)-BB, regulated on activation normal t cell expressed and secreted (RANTES), tumor necrosis
factor (TNF)-α, TNF-β, soluble receptors TNF-sRI, TNF-sRII, macrophage colony-stimulating factor
(M-CSF), B-lymphocyte chemo attractant (CXCL13), I-309, intercellular adhesion molecule (ICAM)-1,
monokine induced by gamma interferon (MIG), tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2.
Samples were evaluated in accordance with the instructions of the manufacturer. Briefly, one
array was run to optimize the serum dilutions at which the cytokines would be quantified within the
array’s limit of detection. All plasma samples and standards were incubated on the arrays at 4 ◦C
and stored overnight with gentle shaking. After several washes, the detection antibody cocktail of
Streptavidin-enzyme horseradish peroxidase conjugated was added, and the arrays were incubated at
room temperature. After another series of washes and incubations, the reaction was stopped and the
cytokine concentration was calculated. The data were expressed in pg/mL.
2.4. Data Analysis
Statistical analysis was performed using the Statistic 6 version Software. Categorical data were
described by absolute frequencies and percentages and the continuous variables as median and
standard error. The Kolmogorov-Smirnov and Shapiro-Willkie tests of normality were applied to
analyze the normal distribution of the variables.Differences between groups and in respect to disease
severity were determined by Student independent t tests. The associations between qualitative
variables were evaluated by Fisher exact tests. Statistical significance was defined as p < 0.05.
3. Results
3.1. Clinical and Demography Description of the Group
The demography and clinical characteristics of autistic patients are summarized in Table 1.
The total number was grouped to minimize comorbidities and other factors susceptible to introduce
controversial results. Autistic patients (12 male/5 female; mean age 6.17 ± 2.08) and 15 age control
subjects (10 male/7 female; mean age 6.5 ± 1.65) were evaluated. The disease severity was distributed
as follow: 64.7% classified as moderate, 29.4% classified as mild, and 5.88% classified as severe.
3.2. EEG Assessment Records in Autistic Patients
All patients showed interictal epileptiform activity with EEG, however, 37.5% of them had
epilepsy. The abnormalities with EEG were focused on brain frontal-temporal region in 50% of the
autistic patients tested, but it was not significantly associated with epilepsy (Fisher exact test p = 0.58).
Figures 1 and 2 represent the EEG measures in autistic patients with and without epileptic seizures.
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Figure 1. Routine awake  electroencephalography (EEG) study in patient with ASD with epileptic 
seizures. Note EEG independently epileptiform abnormality in channels containing the frontal and 
temporal leads in both hemispheres. Maximum amplitude occurred in F8, T4, Fp1, and F3. 
 
Figure 2. Sleep electroencephalography study in a patient with ASD without epileptic seizures. 
Recordings involve complete electroencephalogram, chin electromyography, eye movements, and 
electrocardiogram. Note EEG epileptiform abnormality in channels containing the right centro 
parieto-temporal leads, C4, P4, T4, and T6. 
3.3. Cytokine Profile Level in ASD 
Plasma levels of IL-4, IL-7, IL-10, and TNF-α, IL-12p40, and IFNγ were higher in the ASD group 
than those observed in AMTD, but they did not reach statistical significance after correction for 
Figure 1. Routine awake electroencephalography (EEG) study in patient with ASD with epileptic
seizures. Note EEG independently epileptiform abnormality in channels containing the frontal and
temporal leads in both hemispheres. Maximum amplitude occurred in F8, T4, Fp1, and F3.
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Figure 2. Sleep electroencephalography study in a patient with ASD without epileptic seizures.
Recordings involve complete electroencephalogram, chin electromyography, eye movements, and
electrocardiogram. Note EEG epileptiform abnormality in channels containing the right centro
parieto-temporal leads, C4, P4, T4, and T6.
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3.3. Cytokine Profile Level in ASD
Plasma levels of IL-4, IL-7, IL-10, and TNF-α, IL-12p40, and IFNγ were higher in the ASD group
than those observed in AMTD, but they did not reach statistical significance after correction for
multiple comparisons. Student t test rich differences of cytokines levels were as follow: IL-1β (t = 3.245,
p = 0.0028), IL-6 (t = 3.439, p = 0.0017), IL-17 (t = 7.712, p = 0.0000), IL-12p40 (t = 2.917, p = 0.0065), and
IL-12p70 (t = 3.758, p = 0.0007), in the autistic group compared with the corresponding values of the
AMTD group. Figure 3 shows the median values of cytokines that differed between the ASD patient
group and the control group. Values are given as median ± SEM.
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Figure 3. Plasma cytokine levels in Autism spectrum disorders (ASD) patients and controls. 
Significant data are showed as median ±SEM. Significant levels to *p < 0.05, **p < 0.001, and ***p < 
0.001, t Student test. 
3.4. Cytokine Profile and Behavioral Clinical Outcomes in Autistic Group 
Cytokine Profile and Disease Severity in Autistic Patients 
Autistic patients were divided into two subgroups: patients with moderate (PMDS) and mild 
(PmDS) severity. Autistic patients with severe state of the disease were excluded from the analysis  
(n = 1). Differences in respect to disease severity were observed in IL-1β, IL-6, TNFα, IL-17, IL-12p40 
and IL-12p70. 
The comparison of patients with different degrees of severity with respect to the control group 
shows differences as follow: autistic patients with mild disease severity showed significant 
differences in IL-1β (t = 2.61, p = 0.017), IL-6 (t = 3.68, p = 0.0015), IL-17(t = 4.45, p = 0.0002), and 
IL-12p40 (t = 3.27, p = 0.0039) (see Figure 4a), while autistic patients with moderate disease severity 
showed significant differences in IL-1β (t = 3.01, p = 0.006), IL-6(t = 3.48, p = 0.0022), IL-17 (t = 7.69, p = 
0.000), TNFα (t = 2.61, p = 0.0162), and IL-12p70 (t = 4.22, p = 0.0004) (see Figure 4b). 
The comparison between the patients with mild disease severity (mDS) and moderate disease 
severity (MDS) showed that there were higher levels of IL-12p40 in patients with mild disease 
severity and higher levels of IL-6, TNFα, and IL-12p70 cytokine in patients with moderate severity of 
the disease. Nevertheless, the t Student test shows significant differences only in TNFα when 
comparing both groups. IL-1β levels were similar in both groups (see Figure 4c). 
Figure 3. Plasma cytokine levels in Autism spectrum disorders (ASD) patients and controls.
Significant data are showed as median ±SEM. Significant levels to * p < 0.05, ** p < 0.01, and
*** p < 0.001, t Student test.
3.4. Cytokine Profile and Behavioral Clinical Outcomes in Autistic Group
Cytokine Profile and Disease Severity in Autistic Patients
Autistic patients were divided into two subgroups: patients with moderate (PMDS) and mild
(PmDS) severity. Autistic patients with severe state of the disease were excluded from the analysis
(n = 1). Differences in respect to disease severity were observed in IL-1β, IL-6, TNFα, IL-17, IL-12p40
and IL-12p70.
The comparison of patients with different degrees of severity with respect to the control group
shows differences as follow: autistic patients with mild disease severity showed significant differences
in IL-1β (t = 2.61, p = 0.017), IL-6 (t = 3.68, p = 0.0015), IL-17(t = 4.45, p = 0.0002), and IL-12p40 (t = 3.27,
p = 0.0039) (see Figure 4a), while autistic patients with moderate disease severity showed significant
differences in IL-1β (t = 3.01, p = 0.006), IL-6 (t = 3.48, p = 0.0022), IL-17 (t = 7.69, p = 0.000), TNFα
(t = 2.61, p = 0.0162), and IL-12p70 (t = 4.22, p = 0.0004) (see Figure 4b).
The comparison between the patients with mild disease severity (mDS) and moderate disease
severity (MDS) showed that there were higher levels of IL-12p40 in patients with mild disease severity
and higher levels of IL-6, TNFα, and IL-12p70 cytokine in patients with moderate severity of the
disease. Nevertheless, the t Student test shows significant differences only in TNFα when comparing
both groups. IL-1β levels were similar in both groups (see Figure 4c).
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Figure 4. (a) Plasma cytokines level in autistic patients with mild disease severity and controls. Data 
are shown as median ±SEM. Significant differences, *p < 0.05, ** p < 0.001. t-Student test, PmDS (Mild 
disease severity); (b) Plasma cytokines level in autistic patients with moderate disease severity and 
controls. Data are shown as median ± SEM. Significant differences, * p < 0.05, ** p < 0.001.  
t-Student test, PMDS (Moderate disease severity); (c) Plasma cytokines level in autistic patients with 
mild and moderate disease severity. Data are shown as median ± SEM. Significant differences,  
* p < 0.05. t-Student test, (PmDS vs. PMDS): Mild vs. Moderate disease severity. 
3.5. Cytokine Profile and EEG Findings in Autistic Patients 
Following the EEG measures showed in this analysis, patients were classified as either 
individuals with history of epilepsy or without history of epilepsy.Higher median values of IL-12 
Figure 4. (a) Plasma cytokines level in autistic patients with mild disease severity and controls. Data are
shown as median ±SEM. Significant differences, * p < 0.05, ** p < 0.01. t-Student test, PmDS (Mild
disease severity); (b) Plasma cytokines level in autistic patients with moderate disease severity and
controls. Data are shown as median ± SEM. Significant differences, * p < 0.05, ** p < 0.01, *** p < 0.001.
t-Student test, PMDS (Moderate disease severity); (c) Plasma cytokines level in autistic patients with
mild and moderate disease severity. Data are shown as median ± SEM. Significant differences,
* p < 0.05, ** p < 0.01. t-Student test, (PmDS vs. PMDS): Mild vs. Moderate disease severity.
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3.5. Cytokine Profile and EEG Findings in Autistic Patients
Following the EEG measures showed in this analysis, patients were classified as either individuals
with history of epilepsy or without history of epilepsy.Higher median values of IL-12 p40 was found
in autistic patients with history of epilepsy compared to those without epilepsy (z = 2.23, p = 0.025).
On the other hand, IL-6 levels were higher in patients without epilepsy (z = 2.30, p = 0.021), underlined
by an interictal epileptiform activity focused in the frontal brain region.
4. Discussion
Cytokines are molecules with autocrine, paracrine, and endocrine functions which act to regulate
the cross talk between the immune and nervous system via receptors expressed in neural and
immune cells. In this context, precursors of mature neuronal cells became specialized to modulate the
neurogenesis processes at time that can be influenced to induce an aberrant maturation, proliferation,
and survival of neuron precursor cells [3,25].
Despite the dogma that peripheral immune responses could not affect central nervous system
(CNS) function under normal circumstances, substantial evidence over the past 10 years suggests that
immune-CNS cross-talk may be the norm rather than the exception. Thus, peripheral immune cells can
alter cognition in the absence of CNS immune cell infiltration, suggesting that neural-immune cross-talk
may involve more than the simple “breaching” of the blood brain barrier (BBB). Multiple members
of the large family of cytokines are normally produced in the healthy brain where they play critical
roles in almost every aspect of neural development, including neurogenesis, migration, differentiation,
synapse formation, plasticity, and responses to injury [26,27]. As such, the early cytokine alteration
influencing the brain function may identify the onset of developmental disorders like autism as well
as underline a particular pattern of disease progression or severity [28–30].
Multiples papers reporting immune changes in autism were based on cytokine analysis [31–37].
In the last five years, more than 700 published articles have reported differential patterns of cytokine
and other mediators in fluids and brain tissue of individuals with ASD (data taken from PubMed
Central, August 2016), nevertheless there has not been a consensus on the contribution of cytokine to
clinical behavioral outcome and comorbidities [38,39].
Changes to plasma cytokine levels in individuals with ASD have provided evidence of immune
dysfunction associated with or without an impaired behavioral outcome. Indeed, Ashwood and
colleagues found significant increases of IL-1β, IL-6, IL-8, and IL-12p40 in the plasma of autistic
patients predominantly showing a severe disease form [31], whereas other research groups reported
no association between clinical assessment and cytokine profile in autism [40–43].
IL-1β plays a key role mediating severe placental damage and neurodevelopmental anomalies
in offspring [44]. From this point of view, our results reinforce its potential involvement in the
physiopathology of autism. Evidence of variations in plasma IL-1β levels in children with ASD
have been shown: (1) higher levels were found in high-functioning children with ASD and adults
with severe ASD compared with unrelated controls [45]; (2) higher levels of IL-1β were shown to
have been released both at baseline and after stimulation with Toll like receptor (TLR)2 or TLR4 [45]
from peripheral blood cells from subjects with ASD [31]; and (3) increased cytokine production of
IL-1β levels were found in children with regressive forms of ASD. Other published studies also have
considered high levels of IL-1β in fetal brains suggesting that IL-1β may have a deleterious impact on
the development of the central nervous system [44,46].
The IL-17 is a pro-inflammatory cytokine that is secreted by a specific T-cell subset termed
Th-17 in response to inflammatory stimulus and has been identified as the major regulator of CNS
autoimmunity. This cytokine induces the release of IL-6 and synergizes with IL-1β to mediate the
autoimmune mechanism [47]. In this line of findings, the peripheral upregulation of IL-17 and IL-1β
observed in this study could suggest their role in the neurotoxicity reported in autism, supported by an
autoimmune mechanism, similar to those reported in other neurodegenerative disorders like multiple
sclerosis [48]. Specific associated EEG patterns are used to classify different epilepsy syndromes.
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So, regional electrographic abnormalities in concurrence with molecular changes could be useful for
establishing major and earlier precision of diagnosis of the disease, thereby likely having a favorable
impact on treatment and prognosis.
Autism is characterized by a complex interaction of genetic, environmental, and immunological
factors. The IL-1/IL-17 axis exhibits a pro-inflammatory effect on immune and neural cells, inducing
the differentiation of naïve CD4 T cells via IL-1, and promoting their differentiation to naïve Th17
cells with the secretion of IL-17 cytokines. So, in the context of an up-regulated pro-inflammatory
response, the aberrant chronic inflammatory response in autism can be amplified with negative effects
on the brain. It is well known that IL-17 acting on inflammatory brain cells induces major secretion of
IL-1β, TNFα, and MMP9 which causes neurotoxicity and neuronal death by an apoptotic mechanism.
Increased levels of IL-1 and IL-17 observed in autism support this hypothesis. At the same time, the
measures of TNFα in patients with moderate disease severity suggest apoptosis during a critical stage
of neurodevelopment.
Many children and adults with a diagnosis of ASD have comorbid health problems.
Recent large-scale studies have confirmed that several medical conditions are significantly more
prevalent in people with autism compared to the typical population [49–51]. It has been suggested
that these conditions may be markers for underlying pathology and require a more varied
treatment approach.
Epilepsy and autism, for example, are common comorbidities [50,52], although besides the
prevalent correlation between both disorders, there are not enough reports contributing to clarify
the molecular mechanism involved. Behavioral differences have been reported inautistic patients
displaying different EEG patterns [53,54]. In this paper, differential changes in IL-6 and IL-12p40
related to EEG findings, thereby suggesting that a down-regulated expression of IL-6 in combination
with an up-regulated IL-12p40 could be an element related to a risk of epilepsy comorbidity in autism.
A pathological increase in IL-6 secretion can be the result of an up-regulation of IL-1β in
individuals with autism [55] at the time that IL-1β also acts to induce the expression of transcription
factors, such as NFkB, which also somewhat controls the expression of genes encoding other cytokines,
such as IL-6 and INFγ. In this context, changes observed in this paper to IL-6 could be considered
not only to support considerations surrounding neuroinflammation in autism, but also to supportits
potentialas a peripheral marker in the interpretation of clinical findings related to comorbidities
in autism, with the particular suggestion of considering the frontal localization of epileptic focus,
since the frontal pathology is prominent in autism [56]. Changes in IL-6 levels could contribute to
the understanding of the molecular phenotype associated with the expression of varying degrees
of ASD comorbidity.These data support a model of molecular evidence linking phenotype and
endophenotype associated with immune system dysregulation, and supporting cytoarchitectural
changes which may be mediated by immune response [56–58]. The cerebral cortex provides the
mainboard of critical circuitry that ensure the emergence of higher cognitive functions such as language,
memory, and attention, among others. Bailey and colleagues were pioneering studies emphasizing
the role of cerebral cortex in the neuropathology of ASD [59]. Nevertheless, it is well known that
an impairments of corticogenesis themselves induce a neurodevelopmental disorder, manifested by
deficits in neuronal migration that also promote excitatory/inhibitory bias capable of explaining the
occurrence of comorbid seizure disorder.
The interpretation of many of the clinical findings in ASD appears related to the minicolummnar
pathology and the inhibitory defect in the cerebral cortex in these individuals focused around its
minicolumnar organization [56,60]. So, the inhibitory deficit procreated by the minicolumnopathy,
offers a suitable relationship with the seizures observed in many autistic patients [60,61]. Following this
line of thought, a maldeveloped cytoarchitecture within the prefrontal cortex, in a critical period of
postnatal development, could be related to a dysregulated autoimmune reaction, which may result
in neurotoxicity and neuronal death, thus impacting neural connectivity or inducing atypicalneural
connectivity as measured by EEG.
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Differences have been reported by other studies, like those published by Saresella and
Napoleoni [62,63], which referred to the influence of environmental stimulus acting to induce
neurotoxicity. This process could affect the natural “pruning process” of apoptosis, which is essentially
necessary to the formation of optimal neural pathways during the early stages of typical development,
a feature to consider for future research projects. The great complexity of abnormal brain architecture,
the dysregulated synaptic plasticity and the aberrant heterogeneity of the immune reaction occurring
in this disorder [31,62,63] are main elements to explore to depth of this pathology. Nevertheless, clinical
protocols continue to be necessary to obtain major comprehension on the altered neural plasticity and
behavioral features of these patients.
A prolonged local inflammatory stimulus has been underlined as a vulnerable factor which
may induce neuronal toxicity, hyperexcitability, and higher susceptibility to damage. The changes
in peripheral cytokines observed in this study in relationship to clinical and paraclinical parameters
support the hypothesis on an impaired neuroplasticity occurring in autism [12–16,34,64,65].
A weakness of this preliminary work could be considered from the point of view of the age range
of the patients, since language development changes drastically between the age of three and nine years.
That is why we suggest continuing onwards with this analysis presented here, with impact of ASD on
language, and others measures demonstrating sensitivity to factors based on developmental level and
chronological age suggested for further consideration in future research in order to exclude from the
analysis factors based on developmental level and chronological age with impact on disease severity.
Finally, this article explored the role of cytokines in the expression of ASD, from a different clinical
view point, namely, their influence on the expression of endophenotype by severity, in line with
measures of EEG. Although there is still a debate in the ASD literature, the preliminary evidence of
this paper suggests an interesting relationship for future studies involving ASD severity and comorbid
seizure disorder. The measure of Intelligence Quotient or verbal vs. nonverbal communication could
also represent helpful areas of consideration to be explored in future studies. The results presented in
this paper relating EEG results and ASD severity with immune system dysregulation and the presence
of cytokines as well as the identification of “potential biomarkers” represents an interesting discovery
to be explored with further depth in future studies.
5. Conclusions
This article presents a preliminary finding regarding the role of cytokines on the expression of
ASD, describing the molecular process of immune response and also the role of cytokines (biomarkers)
on the expression of endophenotype by severity, in line with measures of EEG. Although still a debate
in the ASD literature, the mechanism by which the immune response is described here suggests an
interesting relationship and could inform future studies examining ASD severity and comorbid seizure
disorder. The finding relating brain function to immune response further supports existing evidence
that peripheral toxins cross the blood brain barrier and may have a more significant contribution
to the expression of ASD as a result of neurotoxicity and dysregulated immune response during a
critical period of neural development. This process could affect the natural “pruning process” of
apoptosis, which is considered essential for forming efficient neural pathways during the early stages
of typical development. Additionally, other measures demonstrating sensitivity to factors based on
developmental level and chronological age are suggested for future studies in order to exclude factors
based on developmental level and chronological age with impact on disease severity. Other studies
must also consider clinical measure like verbal vs. nonverbal communication, which might be helpful
to confirm evidence presented in this paper.
At the same time, the aberrant connectivity (see above) also shows an impact on the expression
of behavioral patterns of ASD in line with comorbid seizure disorder. In this case, other studies
measuring EEG predictive validity with ASD diagnosis and severity according to a more clearly
defined standard of clinical phenotype and endophenotype would be useful to reduce probable
confounds of heterogeneity within the individuals with ASD studied.
Behav. Sci. 2016, 6, 29 11 of 14
Acknowledgments: The authors appreciate the contribution of all parents of children and give special
acknowledgments to everyone who waswilling to participate in this study.
Author Contributions: All authors contributed substantially to the work reported. Martha Cecilia Inga Jácome
participated in the designer of the research, analysis and discussion of the results, and wrote the manuscript.
Hector Vera Cuesta, Carlos Maragoto Rizo, Mabel Whilby Santiesteban and Lesyanis Ramos Hernández
contributed with the diagnosis and clinical data of patients. Lilia Maria Morales Chacòn contributed
with EEG assessment, and to writing the paper. Elena Noris García contributed to results analysis and
discussion. Maria Elena González Fraguela and Caridad Ivette Fernandez Verdecia contributed to writing
the paper and results analysis. Yamilé Vegas Hurtado performed the technical work. Dario Siniscalco and
Carlos Alberto Gonçalves contributed with analysis tools, discussion of the results and review of the manuscript.
Maria de los Angeles Robinson Agramonte conceived and designed the experiments, participated in the analysis
and discussion of the results and review of the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Lintas, C.; Persico, A.M. Autistic phenotypes and genetic testing: State-of-the-art for the clinical geneticist.
J. Med. Genet. 2009, 46, 1–8. [CrossRef] [PubMed]
2. Goines, P.; Haapanen, L.; Boyce, R.; Duncanson, P.; Braunschweig, D.; Delwiche, L.; Hansen, R.;
Hertz-Picciotto, I.; Ashwood, P.; van de Water, J. Autoantibodies to cerebellum in children with autism
associate with behavior. Brain Behav. Immun. 2011, 25, 514–523. [CrossRef] [PubMed]
3. Garay, P.A.; McAllister, A.K. Novel roles for immune molecules in neural development: Implications for
neurodevelopmental disorders. Front. Synaptic. Neurosci. 2010, 2, 136. [CrossRef] [PubMed]
4. Aktas, O.; Smorodchenko, A.; Brocke, S.; Infante-Duarte, C.; Schulze, T.U.; Vogt, J.; Prozorovski, T.; Meier, S.;
Osmanova, V.; Pohl, E.; et al. Neuronal damage in autoimmune neuroinflammation mediated by the death
ligand TRAIL. Neuron 2005, 46, 421–432. [CrossRef] [PubMed]
5. Arima, Y.; Harada, M.; Kamimura, D.; Park, J.H.; Kawano, F.; Yull, F.E.; Kawamoto, T.; Iwakura, Y.; Betz, U.A.;
Marquez, G.; et al. Regional neural activation defines a gateway for autoreactive T cells to cross the
blood-brain barrier. Cell 2012, 148, 447–457. [CrossRef] [PubMed]
6. Odoardi, F.; Sie, C.; Streyl, K.; Ulaganathan, V.K.; Schlager, C.; Lodygin, D.; Heckelsmiller, K.; Nietfeld, W.;
Ellwart, J.; Klinkert, W.E.; et al. T cells become licensed in the lung to enter the central nervous system.
Nature 2012, 488, 675–679. [CrossRef] [PubMed]
7. Aube, B.; Levesque, S.A.; Pare, A.; Chamma, E.; Kebir, H.; Gorina, R.; Lecuyer, M.A.; Alvarez, J.I.;
de Koninck, Y.; Engelhardt, B.; et al. Neutrophils mediate blood-spinal cord barrier disruption in
demyelinating neuroinflammatory diseases. J. Immunol. 2014, 193, 2438–2454. [CrossRef] [PubMed]
8. Mostafa, G.A.; Al-Ayadhi, L.Y. The relationship between the increased frequency of serum antineuronal
antibodies and the severity of autism in children. Eur. J. Paediatr. Neurol. 2012, 16, 464–468. [CrossRef]
[PubMed]
9. Careaga, M.; Ashwood, P. Autism spectrum disorders: From immunity to behavior. Methods Mol. Biol. 2012,
934, 219–240. [PubMed]
10. Enstrom, A.M.; Onore, C.E.; van de Water, J.A.; Ashwood, P. Differential monocyte responses to TLR ligands
in children with autism spectrum disorders. Brain Behav. Immun. 2010, 24, 64–71. [CrossRef] [PubMed]
11. Ng, T.K.; Fortino, V.R.; Pelaez, D.; Cheung, H.S. Progress of mesenchymal stem cell therapy for neural and
retinal diseases. World J. Stem Cells 2014, 6, 111–119. [CrossRef] [PubMed]
12. Tuchman, R.; Hirtz, D.; Mamounas, L.A. NINDS epilepsy and autism spectrum disorders workshop report.
Neurology 2013, 81, 1630–1636. [CrossRef] [PubMed]
13. Tuchman, R. Autism and social cognition in epilepsy: Implications for comprehensive epilepsy care.
Curr. Opin. Neurol. 2013, 26, 214–218. [CrossRef] [PubMed]
14. Tuchman, R.; Cuccaro, M. Epilepsy and autism: Neurodevelopmental perspective. Curr. Neurol. Neurosci. Rep.
2011, 11, 428–434. [CrossRef] [PubMed]
15. Tuchman, R.; Alessandri, M.; Cuccaro, M. Autism spectrum disorders and epilepsy: Moving towards a
comprehensive approach to treatment. Brain Dev. 2010, 32, 719–730. [CrossRef] [PubMed]
16. Tuchman, R.; Moshe, S.L.; Rapin, I. Convulsing toward the pathophysiology of autism. Brain Dev. 2009, 31,
95–103. [CrossRef] [PubMed]
Behav. Sci. 2016, 6, 29 12 of 14
17. Khandaker, G.M.; Stochl, J.; Zammit, S.; Lewis, G.; Jones, P.B. A population-based longitudinal study of
childhood neurodevelopmental disorders, IQ and subsequent risk of psychotic experiences in adolescence.
Psychol. Med. 2014, 44, 3229–3238. [CrossRef] [PubMed]
18. Tuchman, R.; Rapin, I. Epilepsy in autism. Lancet Neurol. 2002, 1, 352–358. [CrossRef]
19. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators;
Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders—Autism and
Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill. Summ. 2012,
61, 1–19.
20. McKnight, W.; Shafer, E.; Wray, C. New autism spectrum criteria proposed: Some who qualify for diagnosis
might not after 2013. Pediatr. Ann. 2012, 41, 89. [CrossRef]
21. Battle, D.E. Diagnostic and Statistical Manual of Mental Disorders (DSM). Codas 2013, 25, 191–192. [CrossRef]
[PubMed]
22. Beighley, J.S.; Matson, J.L.; Rieske, R.D.; Jang, J.; Cervantes, P.E.; Goldin, R.L. Comparing challenging
behavior in children diagnosed with autism spectrum disorders according to the DSM-IV-TR and the
proposed DSM-5. Dev. Neurorehabil. 2013, 16, 375–381. [CrossRef] [PubMed]
23. Garcia-Lopez, C.; Narbona, J. Clinical usefulness of IDEA and CARS: Concordance with DSM-IV-TR in
children and adolescents with suspicion of PDD. An. Pediatr. (Barc.) 2014, 80, 71–76. [PubMed]
24. George, B.; Padmam, M.S.; Nair, M.K.; Leena, M.L.; Prasanna, G.L.; Russell, P.S. CDC Kerala 11: Diagnosis of
autism among children between 2 and 6 y—Comparison of CARS against DSM-IV-TR. Indian J. Pediatr. 2014,
81 (Suppl. 2), S125–S128. [CrossRef] [PubMed]
25. Goines, P.; van de Water, J. The immune system’s role in the biology of autism. Curr. Opin. Neurol. 2010, 23,
111–117. [CrossRef] [PubMed]
26. Carpentier, P.A.; Dingman, A.L.; Palmer, T.D. Placental TNF-alpha signaling in illness-induced complications
of pregnancy. Am. J. Pathol. 2011, 178, 2802–2810. [CrossRef] [PubMed]
27. Deverman, B.E.; Patterson, P.H. Cytokines and CNS development. Neuron 2009, 64, 61–78. [CrossRef]
[PubMed]
28. Ramos, P.S.; Sajuthi, S.; Langefeld, C.D.; Walker, S.J. Immune function genes CD99L2, JARID2 and TPO show
association with autism spectrum disorder. Mol. Autism 2012, 3, 4. [CrossRef] [PubMed]
29. Mondal, K.; Ramachandran, D.; Patel, V.C.; Hagen, K.R.; Bose, P.; Cutler, D.J.; Zwick, M.E. Excess variants in
AFF2 detected by massively parallel sequencing of males with autism spectrum disorder. Hum. Mol. Genet.
2012, 21, 4356–4364. [CrossRef] [PubMed]
30. Skafidas, E.; Testa, R.; Zantomio, D.; Chana, G.; Everall, I.P.; Pantelis, C. Predicting the diagnosis of autism
spectrum disorder using gene pathway analysis. Mol. Psychiatry 2014, 19, 504–510. [CrossRef] [PubMed]
31. Ashwood, P.; Krakowiak, P.; Hertz-Picciotto, I.; Hansen, R.; Pessah, I.; van de Water, J. Elevated plasma
cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with
impaired behavioral outcome. Brain Behav. Immun. 2011, 25, 40–45. [CrossRef] [PubMed]
32. De Theije, C.G.; Wu, J.; da Silva, S.L.; Kamphuis, P.J.; Garssen, J.; Korte, S.M.; Kraneveld, A.D. Pathways
underlying the gut-to-brain connection in autism spectrum disorders as future targets for disease
management. Eur. J. Pharmacol. 2011, 668 (Suppl. 1), S70–S80. [CrossRef] [PubMed]
33. De Theije, C.G.; Koelink, P.J.; Korte-Bouws, G.A.; Lopes da, S.S.; Korte, S.M.; Olivier, B.;
Garssen, J.; Kraneveld, A.D. Intestinal inflammation in a murine model of autism spectrum disorders.
Brain Behav. Immun. 2014, 37, 240–247. [CrossRef] [PubMed]
34. Garbett, K.; Ebert, P.J.; Mitchell, A.; Lintas, C.; Manzi, B.; Mirnics, K.; Persico, A.M. Immune transcriptome
alterations in the temporal cortex of subjects with autism. Neurobiol. Dis. 2008, 30, 303–311. [CrossRef]
[PubMed]
35. Manzardo, A.M.; Henkhaus, R.; Dhillon, S.; Butler, M.G. Plasma cytokine levels in children with autistic
disorder and unrelated siblings. Int. J. Dev. Neurosci. 2012, 30, 121–127. [CrossRef] [PubMed]
36. Onore, C.; van de Water, J.; Ashwood, P. Decreased levels of EGF in plasma of children with autism spectrum
disorder. Autism Res. Treat. 2012, 2012, 205362. [CrossRef] [PubMed]
37. Singh, V.K.; Warren, R.P.; Odell, J.D.; Cole, P. Changes of soluble interleukin-2, interleukin-2 receptor,
T8 antigen, and interleukin-1 in the serum of autistic children. Clin. Immunol. Immunopathol. 1991, 61,
448–455. [CrossRef]
Behav. Sci. 2016, 6, 29 13 of 14
38. Al-Ayadhi, L.Y.; Mostafa, G.A. A lack of association between elevated serum levels of S100B protein and
autoimmunity in autistic children. J. Neuroinflamm. 2012, 9, 54. [CrossRef] [PubMed]
39. Abrahams, B.S.; Geschwind, D.H. Advances in autism genetics: On the threshold of a new neurobiology.
Nat. Rev. Genet. 2008, 9, 341–355. [CrossRef] [PubMed]
40. Weinstein, A.A.; Deuster, P.A.; Francis, J.L.; Bonsall, R.W.; Tracy, R.P.; Kop, W.J. Neurohormonal and
inflammatory hyper-responsiveness to acute mental stress in depression. Biol. Psychol. 2010, 84, 228–234.
[CrossRef] [PubMed]
41. Petitto, J.M.; Huang, Z.; Meola, D.; Ha, G.K.; Dauer, D. Interleukin-2 and the septohippocampal system:
Intrinsic actions and autoimmune processes relevant to neuropsychiatric disorders. Methods Mol. Biol. 2012,
829, 433–443. [PubMed]
42. Pucak, M.L.; Carroll, K.A.; Kerr, D.A.; Kaplin, A.I. Neuropsychiatric manifestations of depression in multiple
sclerosis: Neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of
immune-mediated depression. Dialogues Clin. Neurosci. 2007, 9, 125–139. [PubMed]
43. Vezzani, A.; Friedman, A. Brain inflammation as a biomarker in epilepsy. Biomark. Med. 2011, 5, 607–614.
[CrossRef] [PubMed]
44. Xu, N.; Li, X.; Zhong, Y. Inflammatory Cytokines: Potential Biomarkers of Immunologic Dysfunction in
Autism Spectrum Disorders. Mediat. Inflamm. 2015, 2015, 531518. [CrossRef] [PubMed]
45. Goines, P.E.; Ashwood, P. Cytokine dysregulation in autism spectrum disorders (ASD): Possible role of the
environment. Neurotoxicol. Teratol. 2013, 36, 67–81. [CrossRef] [PubMed]
46. Enstrom, A.M.; van de Water, J.A.; Ashwood, P. Autoimmunity in autism. Curr. Opin. Investig. Drugs 2009,
10, 463–473. [PubMed]
47. Vojdani, A. The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III. Evid.-Based
Complement. Altern. Med. 2011, 2011, 548086. [CrossRef] [PubMed]
48. Robinson-Agramonte, M.A.; Gonzalez-Quevedo, A.; Goncalvez, C.A. Glial and Axonal Pathology in Multiple
Sclerosis. In Immunology to Target Cancer Inflammation and Infections; Kanwar, J.R., Ed.; InTech: Rijeka, Croatia,
2012; pp. 103–131.
49. Banaschewski, T.; Poustka, L.; Holtmann, M. Autism and ADHD across the life span. Differential diagnoses
or comorbidity? Nervenarzt 2011, 82, 573–580. [CrossRef] [PubMed]
50. Bonus, B.; Assion, H.J.; Deister, A. Coincidence of epilepsy and Asperger syndrome. Case report and review.
Nervenarzt 1997, 68, 759–764. [CrossRef] [PubMed]
51. Chiang, H.L.; Gau, S.S. Comorbid psychiatric conditions as mediators to predict later social adjustment in
youths with autism spectrum disorder. J. Child Psychol. Psychiatry 2015. [CrossRef] [PubMed]
52. Areta, J.E. Two main mistakes in classificatory and clinical function of DSM-IV, in the case of differential
diagnosis between Asperger and autistic disorder. Vertex 2009, 20, 174–183. [PubMed]
53. Clarke, A.R.; Barry, R.J.; Dupuy, F.E.; Heckel, L.D.; McCarthy, R.; Selikowitz, M.; Johnstone, S.J. Behavioural
differences between EEG-defined subgroups of children with Attention-Deficit/Hyperactivity Disorder.
Clin. Neurophysiol. 2011, 122, 1333–1341. [CrossRef] [PubMed]
54. Ballaban-Gil, K.; Tuchman, R. Epilepsy and epileptiform EEG: Association with autism and language
disorders. Ment. Retard. Dev. Disabil. Res. Rev. 2000, 6, 300–308. [CrossRef]
55. Musso, T.; Espinoza-Delgado, I.; Pulkki, K.; Gusella, G.L.; Longo, D.L.; Varesio, L. IL-2 induces IL-6
production in human monocytes. J. Immunol. 1992, 148, 795–800. [PubMed]
56. Casanova, M.F.; van Kooten, I.A.; Switala, A.E.; van Engeland, E.H.; Heinsen, H.; Steinbusch, H.W.; Hof, P.R.;
Trippe, J.; Stone, J.; Schmitz, C. Minicolumnar abnormalities in autism. Acta Neuropathol. 2006, 112, 287–303.
[CrossRef] [PubMed]
57. Casanova, M.F.; Sokhadze, E.; Opris, I.; Wang, Y.; Li, X. Autism spectrum disorders: Linking
neuropathological findings to treatment with transcranial magnetic stimulation. Acta Paediatr. 2015, 104,
346–355. [CrossRef] [PubMed]
58. Bailey, A.R.; Hou, H.; Obregon, D.F.; Tian, J.; Zhu, Y.; Zou, Q.; Nikolic, W.V.; Bengtson, M.; Mori, T.;
Murphy, T.; et al. Aberrant T-lymphocyte development and function in mice overexpressing human soluble
amyloid precursor protein-alpha: Implications for autism. FASEB J. 2012, 26, 1040–1051. [CrossRef] [PubMed]
59. Bailey, A.; Luthert, P.; Dean, A.; Harding, B.; Janota, I.; Montgomery, M.; Rutter, M.; Lantos, P.
A clinicopathological study of autism. Brain 1998, 121, 889–905. [CrossRef] [PubMed]
Behav. Sci. 2016, 6, 29 14 of 14
60. Wang, Y.; Sokhadze, E.M.; El-Baz, A.S.; Li, X.; Sears, L.; Casanova, M.F.; Tasman, A. Relative Power of Specific
EEG Bands and Their Ratios during Neurofeedback Training in Children with Autism Spectrum Disorder.
Front. Hum. Neurosci. 2016, 9, 723. [CrossRef] [PubMed]
61. Tuchman, R. Autism and epilepsy: What has regression got to do with it? Epilepsy Curr. 2006, 6, 107–111.
[CrossRef] [PubMed]
62. Napolioni, V.; Ober-Reynolds, B.; Szelinger, S.; Corneveaux, J.J.; Pawlowski, T.; Ober-Reynolds, S.; Kirwan, J.;
Persico, A.M.; Melmed, R.D.; Craig, D.W.; et al. Plasma cytokine profiling in sibling pairs discordant for
autism spectrum disorder. J. Neuroinflamm. 2013, 10, 38. [CrossRef] [PubMed]
63. Saresella, M.; Marventano, I.; Guerini, F.R.; Mancuso, R.; Ceresa, L.; Zanzottera, M.; Rusconi, B.; Maggioni, E.;
Tinelli, C.; Clerici, M. An autistic endophenotype results in complex immune dysfunction in healthy siblings
of autistic children. Biol. Psychiatry 2009, 66, 978–984. [CrossRef] [PubMed]
64. Tuchman, R.; Cuccaro, M.; Alessandri, M. Autism and epilepsy: Historical perspective. Brain Dev. 2010, 32,
709–718. [CrossRef] [PubMed]
65. Robinson-Agramonte, M.A.; Gonzalez-Fraguela, M.E.; Bergado-Rosado, J. Chapter 7 Autism,
Development and Neural Plasticity. In Translational Approaches to Autism Spectrum Disorder;
Robinson-Agramonte, M.A., Ed.; Springer: Berlin/Heidelberg, Germany, 2015; pp. 119–135.
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
